Country: United States
Language: English
Source: NLM (National Library of Medicine)
LEVETIRACETAM (UNII: 44YRR34555) (LEVETIRACETAM - UNII:44YRR34555)
REMEDYREPACK INC.
LEVETIRACETAM
LEVETIRACETAM 500 mg
ORAL
PRESCRIPTION DRUG
Levetiracetam extended-release tablet is indicated as adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. Levetiracetam extended-release tablet is contraindicated in patients with a hypersensitivity to levetiracetam . Reactions have included anaphylaxis and angioedema [see WARNINGS AND PRECAUTIONS ( 5.4)]. Extended-release levetiracetam tablets levels may decrease during pregnancy [see WARNINGS AND PRECAUTIONS ( 5.9)]. Pregnancy Category C There are no adequate and well-controlled studies in pregnant women. In animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. Extended-release levetiracetam tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Oral administration of levetiracetam to female rats throughout pregnancy and lactation led to increased incidences of minor fetal ske
Levetiracetam Extended-release Tablets USP, 500 mg are white to off white, oblong-shaped, biconvex, film coated tablets, imprinted 'L008' (in black ink) on one side and plain on the other side. They are supplied in white HDPE bottles containing 60 tablets (NDC 68180-117-07) and white HDPE bottles containing 500 tablets (NDC 68180-117-02). Levetiracetam Extended-release Tablets USP, 750 mg are white to off white, oblong-shaped, biconvex, film coated tablets, imprinted 'L009' (in black ink) on one side and plain on the other side. They are supplied in white HDPE bottles containing 60 tablets (NDC 68180-118-07) and white HDPE bottles containing 500 tablets (NDC 68180-118-02). Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Pharmacist: Dispense in a tight, light-resistant container with a child-resistant closure.
Abbreviated New Drug Application
REMEDYREPACK INC. ---------- MEDICATION GUIDE LEVETIRACETAM (LEE-ve-tye-RA-se-tam) EXTENDED-RELEASE TABLETS USP Rx Only Read this Medication Guide before you start taking levetiracetam extended-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about levetiracetam extended-release tablets? Like other antiepileptic drugs, levetiracetam extended-release tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500 people taking it. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: • thoughts about suicide or dying • attempts to commit suicide • new or worse depression • new or worse anxiety • feeling agitated or restless • panic attacks • trouble sleeping (insomnia) • new or worse irritability • acting aggressive, being angry, or violent • acting on dangerous impulses • an extreme increase in activity and talking (mania) • other unusual changes in behavior or mood Do not stop levetiracetam extended-release tablets without first talking to a healthcare provider. • Stopping levetiracetam extended-release tablets suddenly can cause serious problems. Stopping a seizure medicine suddenly can cause seizures that will not stop (status epilepticus). • Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? • Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled. • Call your healthcare provider between visits as needed, especially if you are worried about symptoms. What are levetiracetam exten Read the complete document
LEVETIRACETAM- LEVETIRACETAM TABLET, EXTENDED RELEASE REMEDYREPACK INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LEVETIRACETAM EXTENDED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LEVETIRACETAM EXTENDED-RELEASE TABLETS. LEVETIRACETAM EXTENDED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1999 RECENT MAJOR CHANGES Contraindications ( 4) 3/2017 Warnings and Precautions, Anaphylaxis and Angioedema ( 5.4) 3/2017 Warnings and Precautions, Hematologic Abnormalities ( 5.8) 10/2017 INDICATIONS AND USAGE Levetiracetam extended-release tablet is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy ( 1) DOSAGE AND ADMINISTRATION Initiate treatment with a dose of 1000 mg once daily; increase by 1000 mg every 2 weeks to a maximum recommended dose of 3000 mg once daily ( 2) See full prescribing information for use in patients with impaired renal function ( 2.1) DOSAGE FORMS AND STRENGTHS 500 mg white, film-coated extended-release tablet ( 3) 750 mg white, film-coated extended-release tablet ( 3) CONTRAINDICATIONS Known hypersensitivity to levetiracetam; angioedema and anaphylaxis have occurred ( 4) WARNINGS AND PRECAUTIONS Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed; monitor patients for psychiatric signs and symptoms ( 5.1 ) Suicidal Behavior and Ideation: Monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior ( 5.2) Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on extended-release levetiracetam tablets ( 5.3) Withdrawal Seizures: Extended-release levetiracetam tablets must be gradually withdrawn ( 5.7) ADVERSE REACTIONS Most common adverse reactions (incidence ≥5% more than placebo) include: somnolenc Read the complete document